Press Releases Bayer AG Warsaw S.E.

Equities

BAY

DE000BAY0017

Market Closed - Warsaw S.E. Other stock markets 16:55:46 16/07/2024 BST			5-day change	1st Jan Change
110.2 ^PLN	-3.01%		-0.98%	-23.49%

07-16	ORIC Pharmaceuticals, Inc. Enters into Clinical Trial Collaboration and Supply Agreements with Bayer and Janssen Research & Development, LLC	CI
07-15	BAYER AG : UBS sticks Neutral	ZD

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bayer AG - AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson's disease	07-12	AQ
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	06-26	EQ
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	06-20	EQ
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	05-23	EQ
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	05-22	EQ
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	05-21	EQ
Bayer : Q1 Media Update	05-14	PU
Bayer : First-quarter performance as expected	05-14	PU
Bayer : Debt Investor Information FY 2023 / Q1 2024 (DE)	05-13	PU
Bayer : Debt Investor Information FY 2023 Q1 204	05-13	PU
Bayer : Quarterly Statement First Quarter 2024	05-13	PU
Bayer : Address by Bill Anderson	04-26	PU
Bayer : Address by Bill Anderson	04-22	PU
Bayer : Explanations to the Supervisory Board Report - Prof. Dr. Norbert Winkeljohann	04-22	PU
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	04-17	EQ
Bayer - AskBio Names Mansuo Shannon Chief Scientific Officer	04-10	AQ
Bayer and Vividion Therapeutics to highlight advancing oncology portfolio at AACR 2024 Annual Meeting	04-04	AQ
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	04-03	EQ
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	03-27	EQ
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	03-22	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

BAYER : As soft as anticipated

May 14, 2024 at 07:12 pm

Bayer AG: Not out of the woods yet

March 06, 2024 at 03:46 pm